DrugPatentWatch Database Preview
Calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate - Generic Drug Details
» See Plans and Pricing
What are the generic drug sources for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate and what is the scope of freedom to operate?
Calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
is the generic ingredient in one branded drug marketed by Jazz and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.Calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate has sixty-two patent family members in twenty-three countries.
There are two hundred and eighty-two drug master file entries for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate. One supplier is listed for this compound.
Summary for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
| International Patents: | 62 |
| US Patents: | 10 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 282 |
| Suppliers / Packagers: | 1 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate |
| DailyMed Link: | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate at DailyMed |
Pharmacology for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
| Drug Class | Central Nervous System Depressant |
| Physiological Effect | Central Nervous System Depression Decreased Central Nervous System Organized Electrical Activity |
US Patents and Regulatory Information for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | |||
| Jazz | XYWAV | calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate | SOLUTION;ORAL | 212690-001 | Jul 21, 2020 | RX | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 240874 | Start Trial |
| Mexico | 2015007531 | Start Trial |
| European Patent Office | 3695833 | Start Trial |
| Japan | 2016510031 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for calcium oxybate; magnesium oxybate; potassium oxybate; sodium oxybate
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2365988 | LUC00061 | Luxembourg | Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM ET TOUS LES SELS ET DERIVES DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 2957286 | LUC00094 | Luxembourg | Start Trial | PRODUCT NAME: PATIROMER SORBITEX CALCIUM; AUTHORISATION NUMBER AND DATE: EU/1/17/1179 20170721 |
| 0247633 | 62/1997 | Austria | Start Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
| 0933372 | PA2008006,C0933372 | Lithuania | Start Trial | PRODUCT NAME: FOSAMPRENAVIR CALCIUM; REGISTRATION NO/DATE: EU/1/04/282/001-002 20040712 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2021 - 2022
NCE-1 Patent Challenge Dates 2021 - 2022
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2021, www.DrugPatentWatch.com.
Follow DrugPatentWatch:
